

B Mark Smithers Mbbs, Fracs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6383416/publications.pdf>

Version: 2024-02-01

277
papers

17,315
citations

22153

59
h-index

15732

125
g-index

283
all docs

283
docs citations

283
times ranked

13651
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after totally minimally invasive <i>versus</i> hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group. <i>British Journal of Surgery</i> , 2022, 109, 283-290.	0.3	29
2	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.6	3
3	Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>European Journal of Surgical Oncology</i> , 2022, 48, 1280-1287.	1.0	7
4	Reply to: A practical guide on the use of imiquimod cream to treat lentigo maligna. <i>Australasian Journal of Dermatology</i> , 2022, , .	0.7	0
5	ctDNA as a biomarker of progression in oesophageal adenocarcinoma. <i>ESMO Open</i> , 2022, 7, 100452.	4.5	11
6	Hypothesised cutaneous sites of origin of stage <i>III</i> melanomas with unknown primary: a multicentre study. <i>International Journal of Cancer</i> , 2022, , .	5.1	1
7	Diet quality is associated with primary melanoma thickness. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1745-1750.	2.4	2
8	Patient age and risk of recurrence of primary melanoma at high risk of spread. <i>British Journal of Dermatology</i> , 2021, 184, 566-568.	1.5	3
9	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. <i>Annals of Surgery</i> , 2021, 273, 814-820.	4.2	16
10	Complications and survival after hybrid and fully minimally invasive oesophagectomy. <i>BJS Open</i> , 2021, 5, .	1.7	6
11	Intra-abdominal desmoplastic small round cell tumour in a 56-year-old female: Case report of a very rare presentation of an unusual tumour. <i>International Journal of Surgery Case Reports</i> , 2021, 79, 323-326.	0.6	1
12	Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients. <i>Molecular Cancer Research</i> , 2021, 19, 950-956.	3.4	19
13	Pulmonary metastasectomy in the era of targeted therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2021, 13, 2618-2627.	1.4	12
14	Increased melanoma recurrence in patients with multiple primary invasive melanomas. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	1.2	0
15	Comparative performance of predictors of death from thin (≤ 1.0 mm) melanoma. <i>British Journal of Dermatology</i> , 2021, 185, 849-851.	1.5	3
16	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.7	7
17	Procedure-specific outcomes following gastrectomy for cancer compared by hospital volume and service capability. <i>ANZ Journal of Surgery</i> , 2021, 91, 2430-2435.	0.7	4
18	Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer. <i>JAMA Surgery</i> , 2021, 156, 836.	4.3	41

#	ARTICLE	IF	CITATIONS
19	Hospital characteristics associated with better "quality of surgery" and survival following oesophagogastric cancer surgery in Queensland: a population-level study. ANZ Journal of Surgery, 2021, 91, 323-328.	0.7	7
20	Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy. Health and Quality of Life Outcomes, 2021, 19, 233.	2.4	8
21	Genes Determining Nevus Count and Dermoscopic Appearance in Australian Melanoma Cases and Controls. Journal of Investigative Dermatology, 2020, 140, 498-501.e17.	0.7	13
22	Clinicopathological factors associated with death from thin ($\leq 1.00\text{ mm}$) melanoma. British Journal of Dermatology, 2020, 182, 927-931.	1.5	20
23	Impact of hospital resection volume and service capability on post-operative mortality following gastrectomy. ANZ Journal of Surgery, 2020, 90, 86-91.	0.7	4
24	Pancreaticoduodenectomy in a low-resection volume region: a population-level study examining the impact of hospital-volume on surgical quality and longer-term survival. Hpb, 2020, 22, 1288-1294.	0.3	9
25	The interplay of sun damage and genetic risk in Australian multiple and single primary melanoma cases and controls. British Journal of Dermatology, 2020, 183, 357-366.	1.5	17
26	Baseline neutrophil-lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. Ecological Management and Restoration, 2020, 33, .	0.4	3
27	Intraoperative fluid restriction during enhanced recovery after surgery versus liberal fluids for esophagectomy: A single center retrospective pilot study. Journal of Clinical Anesthesia, 2020, 67, 110030.	1.6	1
28	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 2020, 10, 17687.	3.3	14
29	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	1.0	8
30	Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study. Journal of Cancer Survivorship, 2020, 14, 712-719.	2.9	12
31	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Annals of Surgical Oncology, 2020, 27, 5107-5118.	1.5	8
32	1123P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Initial results in patients refractory to checkpoint blockade. Annals of Oncology, 2020, 31, S755-S756.	1.2	3
33	1125P A phase Ib study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: Results in patients naïve to immune checkpoint blockade. Annals of Oncology, 2020, 31, S756.	1.2	1
34	Highlights of the 2019 Annual Academic Surgery Conference. ANZ Journal of Surgery, 2020, 90, 200-201.	0.7	0
35	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
36	Patterns of Omega-3 and Omega-6 Fatty Acid Dietary Intake and Melanoma Thickness at Diagnosis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1647-1653.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
38	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. Annals of Surgical Oncology, 2020, 27, 1420-1429.	1.5	10
39	Regional nodal metastasis and 5-year survival in patients with thin melanoma in Queensland: a population-based study. ANZ Journal of Surgery, 2020, 90, 503-507.	0.7	3
40	Statins may reduce disease recurrence in patients with ulcerated primary melanoma. British Journal of Dermatology, 2020, 183, 1049-1055.	1.5	10
41	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. JAMA Surgery, 2020, 155, e200397.	4.3	29
42	Prognostic implications of biopsy with tumor transection for patients with high-risk primary melanoma. Journal of the American Academy of Dermatology, 2020, 82, 1521-1524.	1.2	2
43	Accuracy of mobile digital teledermoscopy for skin self-examinations in adults at high risk of skin cancer: an open-label, randomised controlled trial. The Lancet Digital Health, 2020, 2, e129-e137.	12.3	39
44	Long-term deaths from melanoma according to tumor thickness at diagnosis. International Journal of Cancer, 2020, 147, 1391-1396.	5.1	16
45	Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial. Annals of Oncology, 2020, 31, 236-245.	1.2	39
46	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	21.4	138
47	Germline and somatic albinism variants in amelanotic/hypomelanotic melanoma: Increased carriage of TYR and OCA2 variants. PLoS ONE, 2020, 15, e0238529.	2.5	12
48	Esophageal Ulcers. , 2020, , 400-403.		0
49	Title is missing!. , 2020, 15, e0238529.		0
50	Title is missing!. , 2020, 15, e0238529.		0
51	Title is missing!. , 2020, 15, e0238529.		0
52	Title is missing!. , 2020, 15, e0238529.		0
53	Title is missing!. , 2020, 15, e0238529.		0
54	Title is missing!. , 2020, 15, e0238529.		0

#	ARTICLE	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0238529.		0
56	Survival of patients with early invasive melanoma down-staged under the new eighth edition of the American Joint Committee on Cancer staging system. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 272-274.	1.2	11
57	Future is bright for academic surgery in Australasia: highlights of the 2018 Academic Meetings. <i>ANZ Journal of Surgery</i> , 2019, 89, 798-799.	0.7	0
58	Multidisciplinary cancer care in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 197-198.	1.1	2
59	New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes. <i>ANZ Journal of Surgery</i> , 2019, 89, 1187-1189.	0.7	0
60	Assessment of hospital characteristics associated with improved mortality following complex upper gastrointestinal cancer surgery in Queensland. <i>ANZ Journal of Surgery</i> , 2019, 89, 1404-1409.	0.7	3
61	Response to Stahlie et al regarding "A systematic review and meta-analysis of locoregional treatments for in-transit melanoma". <i>Journal of Surgical Oncology</i> , 2019, 120, 1058-1059.	1.7	0
62	Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life. <i>Annals of Surgical Oncology</i> , 2019, 26, 4663-4672.	1.5	3
63	Phenotypic and genotypic analysis of amelanotic and hypomelanotic melanoma patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1076-1083.	2.4	14
64	The Effects of Sharing Awareness Cues in Collaborative Mixed Reality. <i>Frontiers in Robotics and AI</i> , 2019, 6, 5.	3.2	97
65	Risk of Melanoma Recurrence After Diagnosis of a High-Risk Primary Tumor. <i>JAMA Dermatology</i> , 2019, 155, 688.	4.1	74
66	Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	1.5	35
67	Conclusions from quality of life studies in patients with resected high-risk melanoma: one part of the full story. <i>Lancet Oncology</i> , The, 2019, 20, 611-612.	10.7	2
68	The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2375-2384.	1.5	16
69	A systematic review and meta-analysis of locoregional treatments for in-transit melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 887-896.	1.7	24
70	Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study. <i>European Journal of Surgical Oncology</i> , 2019, 45, 832-837.	1.0	4
71	Evaluation of the efficacy of 3D total-body photography with sequential digital dermoscopy in a high-risk melanoma cohort: protocol for a randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e032969.	1.9	27
72	IRF4 rs12203592*T/T genotype is associated with nodular melanoma. <i>Melanoma Research</i> , 2019, 29, 445-446.	1.2	3

#	ARTICLE	IF	CITATIONS
73	Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1264-1272.e6.	0.8	26
74	Sun protection behavior after diagnosis of high-risk primary melanoma and risk of a subsequent primary. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 139-148.e4.	1.2	13
75	Patients with inâ€transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PVâ€10â€”A propensity score matched, single center study. <i>Journal of Surgical Oncology</i> , 2019, 119, 717-727.	1.7	1
76	Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS [®]) Society Recommendations. <i>World Journal of Surgery</i> , 2019, 43, 299-330.	1.6	395
77	Benchmarking Complications Associated with Esophagectomy. <i>Annals of Surgery</i> , 2019, 269, 291-298.	4.2	504
78	Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9559-9559.	1.6	12
79	In response to: Immigration is the most likely reason for the generational change in melanoma incidence in Queensland, Australia. <i>International Journal of Cancer</i> , 2018, 143, 722-723.	5.1	1
80	An investigation into the nutritional status of patients receiving an Enhanced Recovery After Surgery (ERAS) protocol versus standard care following Oesophagectomy. <i>Supportive Care in Cancer</i> , 2018, 26, 2057-2062.	2.2	16
81	Future-proofing academic surgery in Australia and New Zealand: the Annual RACS Joint Academic Meeting. <i>ANZ Journal of Surgery</i> , 2018, 88, 130-131.	0.7	0
82	Neoadjuvant therapy reduces cardiopulmonary function in patients undergoing oesophagectomy. <i>International Journal of Surgery</i> , 2018, 53, 86-92.	2.7	17
83	Intralesional PVâ€10 for the treatment of inâ€transit melanoma metastasesâ€”Results of a prospective, nonâ€randomized, single center study. <i>Journal of Surgical Oncology</i> , 2018, 117, 579-587.	1.7	30
84	Clustering of prevention behaviours in patients with highâ€risk primary melanoma. <i>Psycho-Oncology</i> , 2018, 27, 1442-1449.	2.3	4
85	Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995â€2014. <i>International Journal of Cancer</i> , 2018, 142, 1528-1535.	5.1	107
86	Neoadjuvant therapy for esophageal adenocarcinoma: A propensity score-matched comparison of paclitaxel and carboplatin chemoradiotherapy with cisplatin and 5-fluoruracil-based chemo- or chemoradiotherapy. <i>Annals of Oncology</i> , 2018, 29, viii212.	1.2	0
87	Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. <i>Journal of Surgical Oncology</i> , 2018, 117, 1687-1696.	1.7	20
88	Multicentre factorial randomized clinical trial of perioperative immunonutrition <i>versus</i> standard nutrition for patients undergoing surgical resection of oesophageal cancer. <i>British Journal of Surgery</i> , 2018, 105, 1262-1272.	0.3	39
89	Patterns of Failure Following Dose-escalated Chemoradiotherapy for Fluorodeoxyglucose Positron Emission Tomography Staged Squamous Cell Carcinoma of the Oesophagus. <i>Clinical Oncology</i> , 2018, 30, 642-649.	1.4	3
90	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 916-929.	10.7	131

#	ARTICLE	IF	CITATIONS
91	Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. ANZ Journal of Surgery, 2017, 87, 44-48.	0.7	20
92	Results of a phase II, open-label, non-comparative study of intralesional PV-10 followed by radiotherapy for the treatment of in-transit or metastatic melanoma. Journal of Surgical Oncology, 2017, 115, 891-897.	1.7	18
93	Outcome predictors in median arcuate ligament syndrome. Journal of Vascular Surgery, 2017, 65, 1745-1752.	1.1	41
94	GSTP1 does not modify MC1R effects on melanoma risk. Experimental Dermatology, 2017, 26, 730-733.	2.9	12
95	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2017, 24, 2089-2094.	1.5	22
96	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. New England Journal of Medicine, 2017, 376, 2211-2222.	27.0	1,087
97	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 2017, 24, 2252-2258.	1.5	186
98	Primary cutaneous melanoma of the scalp: Patterns of recurrence. Journal of Surgical Oncology, 2017, 115, 449-454.	1.7	16
99	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. Annals of Surgical Oncology, 2017, 24, 3991-4000.	1.5	102
100	Associations of Statins and Diabetes with Diagnosis of Ulcerated Cutaneous Melanoma. Journal of Investigative Dermatology, 2017, 137, 2599-2605.	0.7	12
101	Use of support services in a sample of patients with high-risk primary melanomas in urban, regional and rural Queensland. Australian and New Zealand Journal of Public Health, 2017, 41, 315-319.	1.8	5
102	Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study. Annals of Surgical Oncology, 2017, 24, 3245-3251.	1.5	16
103	Long-term Health-related Quality of Life Following Esophagectomy. Annals of Surgery, 2017, 265, 1158-1165.	4.2	38
104	Diphenylcyclopropanone for the treatment of cutaneous in-transit melanoma metastases – results of a prospective, non-randomized, single-centre study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 2030-2037.	2.4	20
105	Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study. Supportive Care in Cancer, 2017, 25, 93-102.	2.2	9
106	Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropanone for the management of cutaneous in-transit melanoma metastases – a phase II, single centre, randomised, pilot study. BMJ Open, 2017, 7, e016816.	1.9	13
107	Whither melanoma in Australia?. Medical Journal of Australia, 2017, 207, 330-331.	1.7	7
108	Intralesional rose bengal for stage III and IV melanoma. Annals of Oncology, 2016, 27, vi400.	1.2	0

#	ARTICLE	IF	CITATIONS
109	Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma. <i>International Journal of Cancer</i> , 2016, 139, 664-672.	5.1	7
110	A systematic review of non-surgical treatments for lentigo maligna. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 748-753.	2.4	59
111	Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. <i>Ecological Management and Restoration</i> , 2016, 29, 897-905.	0.4	179
112	Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. <i>Ecological Management and Restoration</i> , 2016, 29, 906-912.	0.4	78
113	Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. <i>Ecological Management and Restoration</i> , 2016, 29, 913-919.	0.4	99
114	Worldwide Esophageal Cancer Collaboration: clinical staging data. <i>Ecological Management and Restoration</i> , 2016, 29, 707-714.	0.4	108
115	Worldwide Esophageal Cancer Collaboration: neoadjuvant pathologic staging data. <i>Ecological Management and Restoration</i> , 2016, 29, 715-723.	0.4	66
116	Worldwide Esophageal Cancer Collaboration: pathologic staging data. <i>Ecological Management and Restoration</i> , 2016, 29, 724-733.	0.4	68
117	Abstract Book: Society of Surgical Oncology 69th Annual Cancer Symposium. <i>Annals of Surgical Oncology</i> , 2016, 23, 1-195.	1.5	22
118	Australian Multicenter Study of Isolated Limb Infusion for Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 1096-1103.	1.5	43
119	Identification of the CIMP-like subtype and aberrant methylation of members of the chromosomal segregation and spindle assembly pathways in esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2016, 37, 356-365.	2.8	46
120	A phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e21072-e21072.	1.6	2
121	Intralesional rose bengal for treatment of melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9600-TPS9600.	1.6	1
122	Australasian College of Dermatologists Abstracts Presented at the 48th Annual Scientific Meeting 16-19 May 2015 Adelaide, South Australia. <i>Australasian Journal of Dermatology</i> , 2015, 56, 1-87.	0.7	14
123	Building a sustainable clinical academic workforce to meet the future healthcare needs of Australia and New Zealand: report from the first summit meeting. <i>Internal Medicine Journal</i> , 2015, 45, 965-971.	0.8	15
124	Prospective study of patterns of surgical management in adults with primary cutaneous melanoma at high risk of spread, in Queensland, Australia. <i>Journal of Surgical Oncology</i> , 2015, 112, 359-365.	1.7	27
125	Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia. <i>Psycho-Oncology</i> , 2015, 24, 763-770.	2.3	49
126	PWE-150 Treatment of oesophageal adenocarcinoma-what is the ideal? results from a survey of augis and anzgosa members. <i>Gut</i> , 2015, 64, A278.2-A279.	12.1	0

#	ARTICLE	IF	CITATIONS
127	Two cases of NSAID-induced gastropathy and enteropathy of the ileum. ANZ Journal of Surgery, 2015, 85, 584-585.	0.7	1
128	International Consensus on Standardization of Data Collection for Complications Associated With Esophagectomy. Annals of Surgery, 2015, 262, 286-294.	4.2	784
129	Australian clinical practice guidelines for the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 804-820.	2.8	104
130	Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. Annals of Surgical Oncology, 2015, 22, 2135-2142.	1.5	126
131	Patterns of Recurrence in Patients with Stage IIIB/C Cutaneous Melanoma of the Head and Neck Following Surgery With and Without Adjuvant Radiation Therapy: Is Isolated Regional Recurrence Salvageable?. Annals of Surgical Oncology, 2015, 22, 4052-4059.	1.5	10
132	Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1049-1060.	10.7	173
133	Changeable naevi in people at high risk for melanoma. Australasian Journal of Dermatology, 2015, 56, 14-18.	0.7	9
134	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, Tj ETQq0 0 0 2gBT /Overlock 10 Tf	2.8	1
135	2200 TOPGEAR: A randomized phase M/MI trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer. Interim results from an international, intergroup trial of the AGITG/TROG/NCIC CTG/EORTC. European Journal of Cancer, 2015, 51, S399-S400.	2.8	1
136	Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma. New England Journal of Medicine, 2014, 370, 599-609.	27.0	1,203
137	Controversies in the management of gastrointestinal stromal tumors. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 216-227.	1.1	6
138	Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma. Journal of Surgical Oncology, 2014, 109, 780-785.	1.7	23
139	Melanoma brain metastases: the impact of nodal disease. Clinical and Experimental Metastasis, 2014, 31, 81-85.	3.3	7
140	Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer, 2014, 17, 152-160.	5.3	12
141	Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. Genes Chromosomes and Cancer, 2014, 53, 324-338.	2.8	38
142	Inducible nitric oxide synthase is a major intermediate in signaling pathways for the survival of plasma cells. Nature Immunology, 2014, 15, 275-282.	14.5	50
143	Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nature Communications, 2014, 5, 5224.	12.8	236
144	BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy. European Journal of Cancer, 2014, 50, 2668-2676.	2.8	67

#	ARTICLE	IF	CITATIONS
145	Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. <i>European Journal of Cancer</i> , 2014, 50, 1301-1309.	2.8	24
146	Total body fat and the risk of Barrett's oesophagus – A bioelectrical impedance study. <i>Cancer Epidemiology</i> , 2014, 38, 266-272.	1.9	14
147	Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9027-9027.	1.6	8
148	Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9050-9050.	1.6	4
149	Neoadjuvant Chemotherapy or Chemoradiotherapy for Locally Advanced Esophageal Cancer. <i>Thoracic Surgery Clinics</i> , 2013, 23, 509-523.	1.0	9
150	Patients undergoing lymphadenectomy for stage III melanomas of known or unknown primary site do not differ in outcome. <i>International Journal of Cancer</i> , 2013, 133, 3000-3007.	5.1	14
151	Surgery and the management of cutaneous melanoma. <i>British Journal of Surgery</i> , 2013, 100, 313-315.	0.3	2
152	Stage III Melanoma in the Axilla: Patterns of Regional Recurrence After Surgery With and Without Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 702-708.	0.8	8
153	Population-Based 20-Year Survival Among People Diagnosed With Thin Melanomas in Queensland, Australia. <i>Journal of Clinical Oncology</i> , 2012, 30, 1462-1467.	1.6	160
154	An innovative approach for locally advanced stage III cutaneous melanoma. <i>Melanoma Research</i> , 2012, 22, 257-262.	1.2	13
155	Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 589-597.	10.7	253
156	Impact of postoperative morbidity on long-term survival after oesophagectomy. <i>British Journal of Surgery</i> , 2012, 100, 95-104.	0.3	60
157	Melanoma Brain Metastases: The Impact of Nodal Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S655.	0.8	0
158	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>Annals of Surgical Oncology</i> , 2012, 19, 2547-2555.	1.5	155
159	A Clinical Risk Prediction Model for Barrett Esophagus. <i>Cancer Prevention Research</i> , 2012, 5, 1115-1123.	1.5	67
160	The influence of prediagnostic demographic and lifestyle factors on esophageal squamous cell carcinoma survival. <i>International Journal of Cancer</i> , 2012, 131, E759-68.	5.1	52
161	Predictors of survival among patients diagnosed with adenocarcinoma of the esophagus and gastroesophageal junction. <i>Cancer Causes and Control</i> , 2012, 23, 555-564.	1.8	27
162	Modeling the Cost-effectiveness of Strategies for Treating Esophageal Adenocarcinoma and High-grade Dysplasia. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 1451-1461.	1.7	11

#	ARTICLE	IF	CITATIONS
163	Prevalence and determinants of frequent gastroesophageal reflux symptoms in the Australian community. <i>Ecological Management and Restoration</i> , 2012, 25, 573-583.	0.4	35
164	Gene expression analysis of EAC in association with PET response.. <i>Journal of Clinical Oncology</i> , 2012, 30, 50-50.	1.6	0
165	Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. <i>Lancet Oncology</i> , The, 2011, 12, 681-692.	10.7	1,467
166	Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. <i>European Journal of Cancer</i> , 2011, 47, 354-360.	2.8	300
167	Dermoscopic naevus patterns in people at high versus moderate/low melanoma risk in Queensland. <i>Australasian Journal of Dermatology</i> , 2011, 52, 248-253.	0.7	9
168	Factors Associated with Postoperative Pulmonary Morbidity After Esophagectomy for Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 1460-1468.	1.5	150
169	Defining Cure for Esophageal Cancer: Analysis of Actual 5-Year Survivors Following Esophagectomy. <i>Annals of Surgical Oncology</i> , 2011, 18, 1766-1774.	1.5	46
170	Minimally invasive esophagectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 981-982.	2.4	0
171	Trends in melanoma incidence among children: possible influence of sun-protection programs. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 661-664.	2.4	21
172	A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 8573-8573.	1.6	4
173	Whole Genome Expression Array Profiling Highlights Differences in Mucosal Defense Genes in Barrett's Esophagus and Esophageal Adenocarcinoma. <i>PLoS ONE</i> , 2011, 6, e22513.	2.5	36
174	Thoracoscopic-Assisted Esophagectomy for Esophageal Cancer. <i>Annals of Surgery</i> , 2010, 252, 281-291.	4.2	42
175	A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. <i>Melanoma Research</i> , 2010, 20, 48-51.	1.2	30
176	Risk Stratification for Early Esophageal Adenocarcinoma: Analysis of Lymphatic Spread and Prognostic Factors. <i>Annals of Surgical Oncology</i> , 2010, 17, 2494-2502.	1.5	86
177	Eating habits and risk of esophageal cancers: a population-based caseâ€“control study. <i>Cancer Causes and Control</i> , 2010, 21, 1475-1484.	1.8	28
178	Symptoms, investigations and management of patients with cancer of the oesophagus and gastroâ€“oesophageal junction in Australia. <i>Medical Journal of Australia</i> , 2010, 193, 572-577.	1.7	20
179	High-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2080-2087.	2.5	80
180	No Role for Melanoma Treatment in the Association between Melanoma and Amyotrophic Lateral Sclerosis or Parkinsonâ€™s Disease. <i>Neuroepidemiology</i> , 2010, 35, 303-304.	2.3	5

#	ARTICLE	IF	CITATIONS
181	Macular Nerve Fiber Layer Thickness. <i>Ophthalmology</i> , 2010, 117, 1053-1053.e1.	5.2	1
182	Minimally invasive esophagectomy: an overview. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 91-99.	3.0	12
183	A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. <i>Investigational New Drugs</i> , 2009, 27, 275-279.	2.6	13
184	Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. <i>Ecological Management and Restoration</i> , 2009, 22, 668-675.	0.4	18
185	Adjuvant Radiotherapy Improves Regional (Lymph Node Field) Control in Melanoma Patients after Lymphadenectomy: Results of an Intergroup Randomized Trial (TROC 02.01/ANZMTG 01.02). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, S2.	0.8	12
186	Isolated Limb Infusion for Malignant Melanoma: Predictors of Response and Outcome. <i>Annals of Surgical Oncology</i> , 2009, 16, 3463-3472.	1.5	37
187	Successful management of an aorto-esophageal fistula caused by a fish bone – case report and review of literature. <i>Journal of Cardiothoracic Surgery</i> , 2009, 4, 21.	1.1	47
188	Cancers of the esophagus and carbonated beverage consumption: a population-based case-control study. <i>Cancer Causes and Control</i> , 2008, 19, 577-584.	1.8	23
189	Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. <i>Annals of Surgical Oncology</i> , 2008, 15, 2894-2902.	1.5	68
190	Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. <i>Ecological Management and Restoration</i> , 2008, 21, 151-158.	0.4	66
191	DESMOPLASTIC MELANOMA: THE ROLE OF RADIOTHERAPY IN IMPROVING LOCAL CONTROL. <i>ANZ Journal of Surgery</i> , 2008, 78, 273-276.	0.7	53
192	Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: Retrospective review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2008, 52, 583-587.	1.8	29
193	Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. <i>Molecular Cancer</i> , 2008, 7, 75.	19.2	52
194	Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1169-1178.	2.5	77
195	Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. <i>Gut</i> , 2008, 57, 173-180.	12.1	259
196	Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High-Density Single-Nucleotide Polymorphism Arrays. <i>Cancer Research</i> , 2008, 68, 4163-4172.	0.9	79
197	Re: Comparison of the Outcomes Between Open and Minimally Invasive Esophagectomy. <i>Annals of Surgery</i> , 2008, 247, 397-398.	4.2	0
198	Consideration of Mesh-Related Complications. <i>Annals of the Royal College of Surgeons of England</i> , 2008, 90, 175-176.	0.6	1

#	ARTICLE	IF	CITATIONS
199	Leptin and the risk of Barrett's oesophagus. <i>Gut</i> , 2007, 57, 448-454.	12.1	126
200	Comparison of the Outcomes Between Open and Minimally Invasive Esophagectomy. <i>Annals of Surgery</i> , 2007, 245, 232-240.	4.2	345
201	Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. <i>Lancet Oncology</i> , The, 2007, 8, 226-234.	10.7	1,137
202	Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy. <i>Ecological Management and Restoration</i> , 2007, 20, 471-477.	0.4	48
203	Two cases of esophageal carcinoma following corrosive esophagitis successfully treated with chemoradiation therapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 108-111.	1.1	2
204	Randomized Clinical Trial of the Effects of Perioperative Use of Immune-Enhancing Enteral Formula on Metabolic Immunological Status in Patients undergoing Esophagectomy. <i>World Journal of Surgery</i> , 2007, 31, 2158-2159.	1.6	7
205	A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. <i>Radiotherapy and Oncology</i> , 2006, 81, 136-142.	0.6	98
206	Radiotherapy for metastatic melanoma presenting in pregnancy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2006, 50, 598-603.	0.6	4
207	Urban-rural differences in survival from cutaneous melanoma in Queensland. <i>Australian and New Zealand Journal of Public Health</i> , 2006, 30, 71-74.	1.8	42
208	Trends for in situ and Invasive Melanoma in Queensland, Australia, 1982-2002. <i>Cancer Causes and Control</i> , 2006, 17, 21-27.	1.8	192
209	Minimally invasive esophagectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2006, 20, 428-433.	2.4	85
210	Cooperative Caching for Chip Multiprocessors. <i>Computer Architecture News</i> , 2006, 34, 264-276.	2.5	141
211	Acute and long-term effect of alpha-glucosidase inhibitor on dumping syndrome in a patient after a vagotomy and pyloric surgery.. <i>ANZ Journal of Surgery</i> , 2005, 75, 1124-1126.	0.7	0
212	Novel approach to oesophageal resection. <i>ANZ Journal of Surgery</i> , 2005, 75, 1029-1029.	0.7	0
213	Cystadenocarcinoma of the pancreas presenting in pregnancy. <i>British Journal of Surgery</i> , 2005, 73, 591-591.	0.3	41
214	Does intercostal blockade improve patient comfort after cholecystectomy?. <i>British Journal of Surgery</i> , 2005, 74, 63-63.	0.3	4
215	Symptomatic and functional outcome after laparoscopic reoperation for failed antireflux surgery. <i>British Journal of Surgery</i> , 2005, 92, 996-1001.	0.3	66
216	Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. <i>International Journal of Clinical Oncology</i> , 2005, 10, 256-261.	2.2	18

#	ARTICLE	IF	CITATIONS
217	Interactions among Smoking, Obesity, and Symptoms of Acid Reflux in Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2481-2486.	2.5	118
218	Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. <i>Lancet Oncology</i> , The, 2005, 6, 659-668.	10.7	876
219	Neoadjuvant chemoradiotherapy in resectable oesophageal cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2005, 6, 825-826.	10.7	21
220	Neoadjuvant chemoradiotherapy in resectable oesophageal cancer. <i>Lancet Oncology</i> , The, 2005, 6, 824-825.	10.7	1
221	Epidemiology of Gastric Cancer. <i>Cancer Reviews: Asia-Pacific</i> , 2004, 02, 1-7.	0.1	2
222	Chemoradiation therapy is effective for the palliative treatment of malignant dysphagia. <i>Ecological Management and Restoration</i> , 2004, 17, 260-265.	0.4	46
223	Use of oesophagogastrosopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. <i>British Journal of Surgery</i> , 2004, 91, 199-204.	0.3	59
224	Relapse Patterns after Chemo-radiation for Carcinoma of the Oesophagus. <i>Clinical Oncology</i> , 2003, 15, 98-108.	1.4	47
225	Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 41-52.	4.2	64
226	High rate of detection of primary aldosteronism, including surgically treatable forms, after non-selective screening of hypertensive patients. <i>Journal of Hypertension</i> , 2003, 21, 2149-2157.	0.5	225
227	The triad of bilateral retinoblastoma, dysplastic naevus syndrome and multiple cutaneous malignant melanomas: a case report and review of the literature. <i>Melanoma Research</i> , 2002, 12, 179-182.	1.2	15
228	Second primary oesophageal cancer following radiation for breast cancer. <i>Radiotherapy and Oncology</i> , 2002, 65, 159-163.	0.6	11
229	Gastric cancer in Australia. <i>Gastric Cancer</i> , 2002, 5, 118-121.	5.3	3
230	Chronic dysphagia following laparoscopic fundoplication. <i>British Journal of Surgery</i> , 2002, 87, 1341-1345.	0.3	46
231	Early reoperation for acute dysphagia following laparoscopic fundoplication. <i>British Journal of Surgery</i> , 2002, 89, 783-786.	0.3	15
232	Radiation therapy following nodal surgery for melanoma: An analysis of late toxicity. <i>ANZ Journal of Surgery</i> , 2002, 72, 344-348.	0.7	51
233	Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. <i>British Journal of Cancer</i> , 2001, 85, 157-165.	6.4	39
234	Thoracoscopic mobilization of the esophagus. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2001, 15, 176-182.	2.4	90

#	ARTICLE	IF	CITATIONS
235	Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. <i>Melanoma Research</i> , 2001, 11, 611-618.	1.2	27
236	Metastatic lesions in the joint associated with acute inflammatory arthritis after dendritic cell immunotherapy for metastatic melanoma. <i>Melanoma Research</i> , 2001, 11, 167-173.	1.2	3
237	Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. <i>Melanoma Research</i> , 2001, 11, 423-431.	1.2	29
238	Localization of small esophageal cancers for radiation planning using endoscopic contrast injection: report on a series of eight cases. <i>Ecological Management and Restoration</i> , 2001, 14, 28-31.	0.4	5
239	Localization of small esophageal cancers for radiation planning using endoscopic contrast injection: report on a series of eight cases. <i>Ecological Management and Restoration</i> , 2001, 14, 28-31.	0.4	0
240	Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?. <i>Melanoma Research</i> , 2000, 10, 47-54.	1.2	12
241	Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?. <i>Melanoma Research</i> , 2000, 10, 47-54.	1.2	8
242	Thirty-four Patients With Carcinoma of the Cervical Esophagus Treated With Chemoradiation Therapy. <i>JAMA Otolaryngology</i> , 2000, 126, 205.	1.2	101
243	Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. <i>Melanoma Research</i> , 1999, 9, 474-482.	1.2	55
244	Title is missing!. , 1999, 9, 187-189.		3
245	LAPAROSCOPY IN THE MANAGEMENT OF DIAPHRAGMATIC RUPTURE DUE TO BLUNT TRAUMA. <i>ANZ Journal of Surgery</i> , 1998, 68, 584-586.	0.7	32
246	Isolated limb perfusion with melphalan for human melanoma xenografts in the hindlimb of nude rats: a surviving animal model. <i>Melanoma Research</i> , 1997, 7, 19-26.	1.2	56
247	Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb. <i>Melanoma Research</i> , 1997, 7, 252-264.	1.2	10
248	A combined modality approach to the management of oesophageal cancer. <i>European Journal of Surgical Oncology</i> , 1997, 23, 219-223.	1.0	19
249	Combined modality therapy for carcinoma of the oesophagus: current status and future directions. <i>Medical Journal of Australia</i> , 1997, 167, 349-350.	1.7	3
250	The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft. <i>British Journal of Cancer</i> , 1997, 75, 1160-1166.	6.4	16
251	Relative dispersion of intravascular transit times during isolated human limb perfusions for recurrent melanoma. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 347-351.	2.4	5
252	Laparoscopic versus Open Appendectomy: Prospective Randomized Trial. <i>World Journal of Surgery</i> , 1996, 20, 17-21.	1.6	217

#	ARTICLE	IF	CITATIONS
253	MALIGNANT SACROCOCCYGEAL GERM CELL TUMOUR IN AN ADULT. ANZ Journal of Surgery, 1996, 66, 185-189.	0.7	4
254	Laparoscopic Nissen fundoplication-200 consecutive cases.. Gut, 1996, 38, 487-491.	12.1	142
255	Laparoscopic Nissen fundoplication and postoperative dysphagia-can it be predicted?. Annals of the Academy of Medicine, Singapore, 1996, 25, 646-9.	0.4	4
256	Radiation therapy for nodal disease in malignant melanoma. World Journal of Surgery, 1995, 19, 369-371.	1.6	70
257	High-performance liquid chromatographic assay for the measurement of melphalan and its hydrolysis products in perfusate and plasma and melphalan in tissues from human and rat isolated limb perfusions. Biomedical Applications, 1995, 673, 267-279.	1.7	26
258	Psychological responses to malignant melanoma. General Hospital Psychiatry, 1995, 17, 126-134.	2.4	64
259	Laparoscopic nephrectomy for benign renal disease. British Journal of Urology, 1994, 73, 237-241.	0.1	12
260	Laparoscopic Approach to the Left Kidney Avoiding Colonic Mobilization. Journal of Urology, 1994, 152, 1967-1969.	0.4	12
261	Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Research, 1994, 4, 365-370.	1.2	40
262	Percutaneous fluoroscopic gastrostomy. Medical Journal of Australia, 1994, 161, 308-310.	1.7	2
263	VIDEOTHORACOSCOPIC PRIMARY REPAIR OF EARLY DISTAL OESOPHAGEAL PERFORATION. ANZ Journal of Surgery, 1993, 63, 399-403.	0.7	9
264	Plasma concentrations of bupivacaine after wound infiltration of an 0.5% solution after inguinal herniorrhaphy: a preliminary study. European Journal of Clinical Pharmacology, 1993, 44, 555-557.	1.9	25
265	Ultrastructure of human melanosis coli with reference to its pathogenesis. Pathology, 1993, 25, 120-123.	0.6	30
266	Desmoplastic melanoma: Patterns of recurrence. World Journal of Surgery, 1992, 16, 186-190.	1.6	112
267	PRIMARY ADENOCARCINOMA IN A COLONIC OESOPHAGEAL SEGMENT. Australian and New Zealand Journal of Surgery, 1992, 62, 158-160.	0.2	9
268	DIAGNOSIS OF RUPTURED DIAPHRAGM FOLLOWING BLUNT TRAUMA: RESULTS FROM 85 CASES. ANZ Journal of Surgery, 1991, 61, 737-741.	0.7	33
269	PRIMARY ADENOCARCINOMA IN A COLONIC OESOPHAGEAL SEGMENT. ANZ Journal of Surgery, 1991, 61, 953-955.	0.7	7
270	DESMOPLASTIC, NEURAL TRANSFORMING AND NEUROTROPIC MELANOMA: A REVIEW OF 45 CASES. ANZ Journal of Surgery, 1990, 60, 967-972.	0.7	85

#	ARTICLE	IF	CITATIONS
271	Construction and Management of Ileostomies and Colostomies. Digestive Diseases, 1989, 7, 265-280.	1.9	2
272	Availability of Organs for Transplantation: A Three Year Study. Journal of Urology, 1987, 137, 811-811.	0.4	0
273	EMERGENCY RIGHT HEMICOLECTOMY IN COLON CARCINOMA: A PROSPECTIVE STUDY. ANZ Journal of Surgery, 1986, 56, 749-752.	0.7	30
274	Availability of organs for transplantation: a three year study.. BMJ: British Medical Journal, 1986, 293, 923-923.	2.3	10
275	Injuries in sport: A prospective casualty study. Medical Journal of Australia, 1985, 142, 457-461.	1.7	13
276	ACTINOMYCOSIS OF THE GALL BLADDER. ANZ Journal of Surgery, 1983, 53, 587-588.	0.7	7
277	Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. Frontiers in Oncology, 0, 12, .	2.8	8